XML 75 R62.htm IDEA: XBRL DOCUMENT v3.25.1
Balance Sheet Components - Intangible Assets, Net (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jun. 26, 2024
Mar. 01, 2024
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Finite-lived assets, net of accumulated amortization of $2,719 and $639, as of December 31, 2024 and 2023, respectively       $ 24,787 $ 41,871  
Accumulated amortization       2,719 639  
Indefinite-lived assets - in-process research and development       28,859 28,859  
Goodwill         943  
Total Intangible assets, net       53,646 71,673  
Amortization expense, Finite-lived intangible assets       3,400    
Expected amortization expense for the remaining finite-lived assets for each of the five succeeding fiscal years       $ 2,700    
Remaining life of the finite-lived assets       9 years 4 months 24 days    
Impairment charge       $ 0 0  
Impairment of intangible assets         $ 0 $ 0
Novartis Institutes            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Impairment charge     $ 10,600      
Disposal Group | CIMERLI ophthalmology franchise            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Finite-lived intangible asset, net   $ 2,100        
Goodwill, Written off   $ 900        
Disposal Group | YUSIMRY Sale            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Goodwill, Written off $ 900